MedTrace Logo

A Relative Bioavailability Study of 50 mg Venlafaxine Hydrochloride Tablets Under Fed Conditions

NCT00871364 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-08-16

No results posted yet for this study

Summary

The purpose of this study to assess the single-dose relative bioavailability of Actavis Group hf 50 mg venlafaxine hydrochloride tablets with Wyeth Pharmaceuticals (Effexor®) 50 mg venlafaxine (as venlafaxine hydrochloride) tablets under fed conditions.

Conditions

  • Healthy

Interventions

DRUG

VENLAFAXINE TABLETS 50 mg , single dose

A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions

DRUG

Effexor® Tablets equivalent to 50 mg venlafaxine

B: Active comparator Subjects received Wyeth Pharmaceuticals Inc. formulated products under fed conditions

Sponsors & Collaborators

  • Actavis Inc.

    lead INDUSTRY

Principal Investigators

  • Gaetano Morelli,, MD · MDS Pharma Services

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2006-05-31
Completion
2006-05-31

Countries

  • Canada

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00871364 on ClinicalTrials.gov